DexCom (DXCM)
(Real Time Quote from BATS)
$128.62 USD
-9.39 (-6.80%)
Updated Apr 26, 2024 11:54 AM ET
3-Hold of 5 3
D Value C Growth C Momentum D VGM
Brokerage Reports
0 items in cart
DexCom, Inc. [DXCM]
Reports for Purchase
Showing records 341 - 360 ( 411 total )
Company: DexCom, Inc.
Industry: Medical - Products
Reports In-line Q2 Sales; Gen4 PMA Remains On Track For Approval Prior to Year-end; Reiterate
Provider: WEDBUSH SECURITIES INC.
Analyst: LAU R
Company: DexCom, Inc.
Industry: Medical - Products
Company: DexCom, Inc.
Industry: Medical - Products
DXCM Feltl CGM Project: Historical survey of 554 CGM users (2007 present)
Provider: FELTL & COMPANY
Analyst: HAYNOR B
Company: DexCom, Inc.
Industry: Medical - Products
LIFE SCIENCES: The Week Ahead in Life Sciences - Upcoming Events for the Week of July 8
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: DexCom, Inc.
Industry: Medical - Products
G4 Receives CE Mark Approval With Phased European Launch Planned Over Coming Months. Reiterate OUTPERFORM and $15 FV
Provider: WEDBUSH SECURITIES INC.
Analyst: LAU R
Company: DexCom, Inc.
Industry: Medical - Products
Company: DexCom, Inc.
Industry: Medical - Products
Impressive Gen4 Data Presented at ADA with Potential FDA Approval by Yearend. Reiterate OUTPERFORM and $15 FV.
Provider: WEDBUSH SECURITIES INC.
Analyst: LAU R
Company: DexCom, Inc.
Industry: Medical - Products
DXCM DexCom presents Gen 4 data at ADA, attrition survey released
Provider: FELTL & COMPANY
Analyst: HAYNOR B
Company: DexCom, Inc.
Industry: Medical - Products
Company: DexCom, Inc.
Industry: Medical - Products
Company: DexCom, Inc.
Industry: Medical - Products
Medical Devices: Pending Legislation Will Increase FDA''s Reach Offset By Some Benefits
Provider: CAPSTONE INVESTMENTS
Analyst: PUTNAM J
Company: DexCom, Inc.
Industry: Medical - Products
LIFE SCIENCES-The Week Ahead in Life Sciences - Upcoming Events for the Week of May 6
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: DexCom, Inc.
Industry: Medical - Products
Q1IN-LINE W/ STREET - GEN4 PMA FILED ON SCHEDULE - BUY
Provider: CAPSTONE INVESTMENTS
Analyst: PUTNAM J
Company: DexCom, Inc.
Industry: Medical - Products
DXCM DexCom reports Q1 2012; maintaining HOLD, raising PT to $10.75
Provider: FELTL & COMPANY
Analyst: HAYNOR B
Company: DexCom, Inc.
Industry: Medical - Products
DXCM Feltl CGM Project: Historical survey of 489 CGM users (2007 present)
Provider: FELTL & COMPANY
Analyst: HAYNOR B
Company: DexCom, Inc.
Industry: Medical - Products
Reports Inline Q1 Sales; Gen4 PMA Filed Allowing for Potential Approval by Year-end; Maintain OUTPERFORM
Provider: WEDBUSH SECURITIES INC.
Analyst: LAU R
Company: DexCom, Inc.
Industry: Medical - Products
Medical Device-notes from first annual Irvine/San Diago " Bus Tour "This report contains brief updates on the following: ELGX, DXCM, CYTX, GPRO, NUVA, RMD, ALR, MASI, SGNT. These companies are covered in more detail in separate Daily Notes and/or Company Reports.
Provider: CAPSTONE INVESTMENTS
Analyst: PUTNAM J
Company: DexCom, Inc.
Industry: Medical - Products
Company: DexCom, Inc.
Industry: Medical - Products
DXCM DexCom reports Q4, acquires SweetSpot; reiterate HOLD, $9.00PT
Provider: FELTL & COMPANY
Analyst: HAYNOR B
Company: DexCom, Inc.
Industry: Medical - Products
SOLID Q4 - PUSHING HARD ON GEN 4- RAISING PT TO $13.50 - BUY
Provider: CAPSTONE INVESTMENTS
Analyst: PUTNAM J